Human cytochrome P450 (CYP) 2D6 is one of the major CYP enzymes involved in hepatic drug metabolism and exhibits genetic polymorphism. Seven percent to 10% of the Caucasian population lack the enzyme, which is due to mutations in the gene localized on chromosome 22.
Propranolol (PL) is a classic b-adrenoceptor antagonist, and is often prescribed as an antihypertensive agent. PL is known as a relatively safe drug with few adverse effects, but chronic administration in humans has been reported to increase its systemic availability. [5] [6] [7] The increase in availability could reflect a decrease in metabolism which has been observed in rats. Repetitive oral administration of PL to rats caused a remarkable decrease in debrisoquine 4-hydroxylase 8) and PL aromatic 4-, 5-, and 7-hydroxylation by rat hepatic microsomal fractions. 9, 10) Since PL ring hydroxylation at positions 4 and 5 is mediated by CYP2D6 in humans, [11] [12] [13] the increase in the systemic availability of PL observed in humans treated with PL might be due to decreased hepatic microsomal CYP2D6 enzyme activities.
We have been interested in the mechanism of the inactivation of the enzyme metabolizing PL in the rat. [14] [15] [16] [17] We have obtained some evidence suggesting that the formation and further metabolism of 4-hydroxypropranolol (4-OH-PL) from PL ( Fig. 1 ) may be involved in the inactivation of CYP2D enzyme(s), the major PL-oxidizing enzyme in the rat. However, the detailed mechanism(s) of the inactivation remains to be elucidated. In this study, we examined the inactivation of rat CYP2D enzyme by 4-OH-PL using substrate and inhibitor as protectors. The results indicate that a transformation product of 4-OH-PL is responsible for the enzyme inactivation.
MATERIALS AND METHODS
Chemicals PL, procainamide, quinine, and quinidine were obtained as hydrochlorides from the Sigma Chemical Co. (St. Louis, MO, U.S.A.); N-desisopropylpropranolol (NDP) hydrochloride was from ICI Pharmaceutical Co. (Macclesfield, U.K.); 1,4-naphthoquinone (1,4-NQ) was from Sigma-Aldrich Japan (Tokyo, Japan); bunitrolol (BTL) hydrochloride was from Nippon Boehringer-Ingelheim Co. (Kawanishi, Japan); and 1,4-dihydroxynaphthalene (1,4-DHN) was from Tokyo Kasei Co. (Tokyo, Japan). 4-OH-PL hydrochloride was supplied by the Sumitomo Chemical Co., Ltd. (Osaka, Japan). 5-OH-PL hydrochloride was synthesized according to the method of Oatis et al. 18 ) (see chemical structures of the compounds used in Fig. 1) . b-NADPH, glucose 6-phosphate (G-6-P) and G-6-P dehydrogenase were purchased from the Oriental Yeast Co., Ltd. (Tokyo, Japan). Other reagents and organic solvents used were of the highest quality commercially available.
Enzyme Sources Adult male Wistar rats (6-7 weeks Repetitive administration of propranolol (PL) in rats decreases the activities of cytochrome P450 (CYP) 2D enzyme(s) in hepatic microsomes. We examined the properties of 4-hydroxypropranolol (4-OH-PL) as an inactivator of rat liver microsomal CYP2D enzyme(s) using bunitrolol (BTL) 4-hydroxylation and PL 5-and 7-hydroxylations as indices of CYP2D enzyme activity. Rat microsomal BTL 4-hydroxylase activity was inhibited by the addition of 4-OH-PL to the incubation medium. The inhibition was greater after preincubation of microsomes with 4-OH-PL in the presence of NADPH than in its absence. The type of inhibition kinetics of BTL 4-hydroxylase by 4-OH-PL was changed from a competitive type to a noncompetitive type by the preincubation. The inhibition of rat liver microsomal PL 5-and 7-hydroxylases by 4-OH-PL was blocked efficiently by co-incubation with quinine, a typical inhibitor of rat CYP2D enzyme(s), or to a lesser extent by BTL. However, quinidine, a diastereomer of quinine, did not significantly protect against the enzyme inactivation. The protective capacities of the substrate and inhibitors reflected their affinities for rat CYP2D enzyme(s). BTL hydroxylase was not affected by either 1,4-naphthoquinone or 1,4-dihydroxynaphthalene which are possible metabolites of 4-OH-PL. These results provide further evidence to support the notion that PL is biotransformed by rat CYP2D enzyme(s) to 4-OH-PL, which is further oxidized to a chemically reactive metabolite in the active site. The inactivation of CYP is likely the result of covalent binding of the reactive species to an amino acid residue of the active site.
old) were obtained from Takasugi Experimental Animals Laboratory (Saitama, Japan). Hepatic microsomal fractions were prepared according to the method of Omura and Sato. 19) Protein concentrations were determined by the method of Lowry et al.
20)
Incubation of Microsomes with Substrates or Inhibitors All microsomal incubations were preceded by an equilibration in which the microsomal preparation (0.5 mg protein) was incubated with G-6-P 10 mM, MgCl 2 8 mM, G-6-P dehydrogenase 1 IU in potassium phosphate buffer 100 mM (pH 7.4) containing EDTA 1 mM in a final volume of 1.0 ml at 37°C for 5 min before the addition of NADPH and substrate.
BTL Hydroxylation According to a published method, 21) the reaction was initiated after equilibration at 37°C by adding BTL (final concentration 10 mM) and NADPH (0.5 mM) and stopped by adding 1 N NaOH (0.5 ml) 1 min later. A 1-min incubation was used to determine initial velocities. Then, 1 ml of sodium carbonate buffer 1 M (pH 9.6) and the internal standard procainamide (20 ng) were added, and the metabolites were extracted into ethyl acetate 5 ml by vigorous shaking and centrifugation.
PL Oxidation This reaction was initiated by adding racemic PL (final concentration 10 mM) and NADPH (0.5 mM) to the equilibrated microsomal mixture. The reaction was allowed to proceed for 1 min, worked up, and the oxidation assay performed according to a published HPLC method.
22)
Exposure of Microsomes to 4-OH-PL In the first series of experiments, NADPH (final concentration 0.5 mM), with or without 4-OH-PL (final concentration 5 mM), was added to the equilibrated mixture, allowed to incubate at 37°C for 5 min, after which BTL (final concentration 10 mM) was added and BTL hydroxylation allowed to proceed for 1 min as depicted in Chart 1 (Procedure 1, A-D). The concentration of 4-OH-PL (5 mM) was employed according to our published results characterizing 1,4-NQ as a further metabolite of 4-OH-PL. 16 ) An additional charge of NADPH was not necessary, as the initial charge of 500 nmol/ml was sufficient. The reaction was quenched by adding sodium carbonate buffer (pH 9.6) and the resulting mixture was subjected to ethyl acetate extraction and evaporation as described above.
To search for a possible difference in the type of inhibition of microsomal BTL 4-hydroxylase by 4-OH-PL with or without preincubation with NADPH, kinetics were determined under the protocol in Chart 1 (Procedure C, D) using a substrate concentration range from 0.4 to 10 mM. In Procedure C, the microsomal preparation was preincubated with NADPH for 5 min, then 4-OH-PL (2 and 10 mM as final concentrations) and varying concentrations of the substrate were added and the hydroxylation reaction was allowed to proceed for 1 min. In Procedure D, the same preparation was preincubated with 4-OH-PL (1 mM) and NADPH for 5 min, and then BTL added to allow hydroxylation. The concentration (1 mM) of 4-OH-PL was chosen because almost all the 4-OH-PL added (1 nmol) was found to be consumed during the preincubation with NADPH in preliminary experiments.
The second series of experiments examined the irreversible effects of 4-OH-PL on microsomes by removing residual 4-OH-PL by washing as summarized in Chart 1 (Procedure 2, A-D). Thus microsomes (4 mg protein) were equilibrated for 5 min at 37°C in the reaction medium (final volume 8 ml) containing G-6-P 10 mM, MgCl 2 8 mM, G-6-P dehydrogenase 5 IU in potassium phosphate buffer 100 mM (pH 7.4) in a 30-ml flask. They were incubated with 4-OH-PL (5 mM) in the presence or absence of NADPH for 5 min, chilled, and the mixture was centrifuged at 4°C for 60 min at 105000ϫg. The resulting pellet was resuspended in 8 ml of potassium phosphate buffer 100 mM (pH 7.4) and recentrifuged. The pellet obtained from this second centrifugation was resuspended in 1 ml of buffer and assayed for BTL hydroxylation activity. The time schedule employed was based on the results obtained in preliminary experiments.
Protection Experiments In studies of the protective effects of a substrate or inhibitors, BTL (final concentration 20 mM), quinine (5 mM), or quinidine (5 mM) was added to the reaction medium as described in the second series of experiments (final volume 8 ml) as the equilibration stage, as shown in Chart 1 (Procedure 2, E). The concentrations of the substrate and inhibitors employed were chosen on the basis of the results obtained in preliminary experiments. Then, 4-OH-PL (5 mM) and NADPH (0.5 mM) were added and the mixture incubated for 5 min at 37°C. The mixture was then chilled and washed twice by centrifugation as described above and the PL 5-and 7-hydroxylation activities determined in the resuspended washed microsomes.
Analytical Procedures BTL 4-hydroxylation 21) and PL oxidation 22) were assayed by HPLC methods previously described. The instrument was a Hitachi 655-type liquid chromatograph equipped with a Hitachi 650-10S fluorescence detector and a Shimadzu Chromatopac RC-3 data processor. The column was an Inertsil ODS (4.6 mmϫ250 mm; GL Science Co., Tokyo, Japan) with a mobile phase of acetonitrile/methanol/water/acetic acid (20 : 20 : 60 : 1 by volume) for PL oxidation products and a mobile phase of acetonitrile/methanol/water/acetic acid (18 : 18 : 64 : 1 by volume) for BTL oxidation. The flow rate was 1 ml/min and detection at 310/380 nm (excitation/emission wavelength). Statistical significance was calculated by ANOVA and the Bonferroni test.
RESULTS
Initially, we examined the time course of PL metabolite formation by rat liver microsomes. Under the conditions used, 7-OH-PL was the most abundant primary metabolite, followed by 4-OH-PL, 5-OH-PL, and NDP (Fig. 2) . The formation of 7-OH-PL and 5-OH-PL showed a peak at 10 min and decreased with time thereafter over 30 min. The levels of 4-OH-PL and 7-OH-PL after 2 min of incubation were almost the same, but the formation of 4-OH-PL did not increase after 5 and 10 min of incubation, which was clearly different from the profile of 7-OH-PL formation. The formation of NDP, on the other hand, reached a plateau and did not show a clear decline. At 30 min, most of the substrate added had disappeared from the incubation mixture. These results suggest that the enzyme converting PL to 4-OH-PL is inhibited or that the 4-OH-PL formed is quickly converted to further metabolite(s).
Next, the effects of 4-OH-PL on CYP2D enzymes were examined after exposing the microsomes to 4-OH-PL 5 mM and NADPH for 5 min, with BTL as the substrate. As shown in Procedure 1 in Chart 1 and the left panel of Fig. 3 , exposure of microsomes to NADPH alone decreased BTL hydroxylation activity (B), possibly by lipid peroxidation of microsomal membranes through the actions of reduced oxygen species generated by NADPH and CYP reductase. When 4-OH-PL (5 mM) and BTL (10 mM) were added together for the 5-min incubation, BTL hydroxylation activity was decreased by 51% of the NADPH control (B vs. C). However, when the 4-OH-PL exposure was carried out in the absence of BTL and the BTL hydroxylation activity determined subsequently, a further decrease to 43% of the NADPH control was observed (C vs. D). These results suggest that the formation of a metabolite of 4-OH-PL during the preincubation with microsomes and NADPH causes a further decrease in the activity.
In the third stage of our study, we subjected the microsomes to ultracentrifugation to remove residual 4-OH-PL from the mixture. As depicted in Procedure 2 of Chart 1 and the right panel of Fig. 3 , the BTL 4-hydroxylase activity of microsomes that were preincubated with NADPH for 5 min followed by ultracentrifugation (B) and that of microsomes that were preincubated with 4-OH-PL for 5 min in the absence of NADPH followed by ultracentrifugation (C) were almost the same as that of the control (A). In contrast, the activity of microsomes that were preincubated with 4-OH-PL and NADPH for 5 min and subjected to ultracentrifugation (D) was significantly lower than that of the control (A) (59% of control). These results further support the notion that the NADPH-dependent formation of a metabolite of 4-OH-PL is responsible for the decreased BTL 4-hydroxylase activity in rat liver microsomes preincubated with 4-OH-PL.
To determine the type of inhibition by 4-OH-PL for microsomal BTL 4-hydroxylation, we performed kinetic studies using microsomes that were preincubated with NADPH alone (Chart 1, Procedure 1-C) or with 4-OH-PL and 
NADPH (Procedure 1-D)
. Without preicubation with NADPH, 4-OH-PL competitively inhibited BTL 4-hydroxylase in rat liver microsomes (Fig. 4A) , whereas it noncompetitively inhibited BTL 4-hydroxylase following preincubation with NADPH (Fig. 4B) . The kinetic parameters are calculated as follows: (A) competitive inhibition, control K m 2.12 mM; V max 2.33 nmol/min/mg protein; and K i 0.749 mM; (B) noncompetitive inhibition, control K m 1.79 mM; V max 3.39 nmol/min/mg protein; and K i 0.647 mM.
The observations thus far were consistent with the actions of 4-OH-PL as an irreversible inhibitor of BTL 4-hydroxylase through its activation by CYP to a reactive metabolite. To assess whether the activation involves CYP2D enzymes, we examined the effects of the 2D substrates BTL and the CYP inhibitors quinine and quinidine on the actions of 4-OH-PL. In preliminary experiments, we found that quinine and quinidine could interfere with the assay of BTL 4-hydroxylation because their retention times were very close to those of 4-OH-BTL under the HPLC conditions employed. For this reason, and to avoid complications from the presence of BTL in the incubation mixture prior to its use as a substrate, we assayed CYP2D activity by following the oxidation of PL to 5-and 7-OH-PL. 22 ) Figure 5 summarizes the effects of BTL (top panels), quinine (middle panels), and quinidine (bottom panels) as protectors against enzyme inactivation. As shown in D, Procedure 2 of Chart 1, exposure of rat liver microsomes to 4-OH-PL and NADPH followed by washing resulted in a decrease in PL 5-and 7-hydroxylase activities to 47% and 44% (Fig. 5  top panel, B) , respectively, of control microsomes that were preincubated with BTL and NADPH under the same conditions (A). After incubation of microsomes with 4-OH-PL and NADPH in the presence of BTL (20 mM) as a protector, a slight protective effect of PL 5-and 7-hydroxylase activities (from 47% to 54% for 5-OH-PL and from 44% to 53% for 7-OH-PL) was observed (C compared with B).
When quinine (5 mM) was used as a protector (middle panels, Fig. 5 ), the protection of the enzyme activities was more marked. The addition of quinine almost completely protected the enzyme against inactivation by 4-OH-PL. In contrast, quinidine (5 mM), a diastereomer of quinine and inhibitor of the human CYP2D enzyme, was much less effective in the protection of the enzyme (Fig. 5, bottom panels) .
The ranked potencies of the protective substrate and inhibitors are quinineϾBTLϾquinidine. Kobayashi et al. 23) demonstrated that quinine is a much more potent inhibitor of rat microsomal CYP2D enzyme(s) compared with its diastereomer, quinidine, which is much more effective as an inhibitor of CYP2D6, the human enzyme. We have already reported that the K m value for BTL 4-hydroxylation by rat liver microsomes was 0.8 to 1.0 mM, and that IC 50 values of quinine and quinidine for inhibition of BTL oxidation (6.25 mM of substrate concentration) were 66 nM and 33.4 mM, respectively. 24) Therefore the protective effects of BTL, quinine, and quinidine against inactivation of rat CYP2D enzyme(s) via further metabolism of 4-OH-PL in the present study reflect their CYP2D kinetic properties examined in our previous study. 24) In other studies, 16, 17) we proposed that 1,4-NQ could be one of the 4-OH-PL metabolites that inactivates CYP2D enzyme(s) by covalent binding. To assess this possibility further, we examined the actions of 1,4-NQ and its reduction product 1,4-DHN on BTL 4-hydroxylation. Interestingly, 1,4-NQ or 1,4-DHN added exogenously did not affect microsomal BTL 4-hydroxylation, irrespective of the absence or presence of NADPH during preincubation (Fig. 6) . 
DISCUSSION
The results of the studies described above and our previous results 16, 17) indicate that inactivation of PL and BTL hydroxylase, probably CYP2D enzyme(s), likely occurs through the actions of a further metabolite of 4-OH-PL. In previous studies, 16) we demonstrated that 4-OH-PL is converted to 1,4-NQ by a superoxide-dependent pathway. 1,4-NQ is a reactive species [25] [26] [27] that readily forms covalent bonds with nucleophilic functions through a 1,4-addition reaction. The compound can also modify thiols by a redox reaction in which reducing equivalents from NADPH are used to reduce oxygen to reactive species such as superoxide and peroxide. [25] [26] [27] Although inactivity of 1,4-NQ would appear to refute the notion of a quinone-based inactivation process, a more subtle process occurring within the active site of the enzyme may account for the lack of effect of 1,4-NQ and 1,4-DHN. The substrate binding site of CYP2D6, the human form of CYP2D, contains an anionic center to which the cationic form of the substrate binds 4, 28) at 5 to 7 Å 29, 30) from the oxidation site. The rat enzyme may share this property of selectivity for compounds containing cationic (at physiological pH) centers 31) so that amine substrates commonly have K m values in the micromolar range. 16, 28, 32, 33) Similar to CYP2D6, there is an aspartic acid residue at position 304 of rat CYP2D2 of which the carboxyl group can trap a heteroatom of its substrates (Fig. 7) . As an amine, 4-OH-PL could bind to the active site of CYP2D2, with its positively charged side chain nitrogen atom binding to the carboxyl group of Asp-304. It could then be converted to 1,4-NQ by superoxide or by oxidation of 1,4-DHN, the initial product of CYP oxidation (Fig. 7C) . The 1,4-NQ formed could then be in close proximity to a nucleophilic center such a cysteine residue in the active site and inactivate the enzyme (Fig. 7D) . Direct exposure of CYP2D to the neutral 1,4-NQ and 1,4-DHN may not be an appropriate test because, although they are capable of enzyme inactivation, they have a low affinity for the active site and may not orient properly within it. Therefore we propose an inactivation process in which a fraction of the bound 4-OH-PL is converted to 1,4-NQ within the active site of the enzyme. Within the active site the 1,4-NQ could inactivate the enzyme by covalent binding to an essential nucleophile and/or reduction of oxygen to superoxide or peroxide. As this chemistry takes place within the active site, the local concentration can be very high. Further studies including identification of a possible adduct to be formed between a further metabolite of 4-OH-PL and amino acid residue(s) of the BTL 4-hydroxylase are necessary to support this proposition.
In summary, we have examined 4-OH-PL as an inactivator of rat liver microsomal CYP2D enzyme(s). CYP2D activity was more effectively inhibited when the microsomes were preincubated with 4-OH-PL in the presence of NADPH than in its absence, indicating that 4-OH-PL is converted to the active inhibitor by a CYP/NADPH-dependent process. The ability of quinine to block PL 5-and 7-hydroxylase inactivation by 4-OH-PL efficiently, the reduced but significant protection against 4-OH-PL by BTL, and the inability of the human CYP2D6 inhibitor quinidine to affect the inactivation reflect their affinities for rat CYP2D. These actions indicate that the inactivation process occurs on CYP2D. Furthermore, the absence of an effect by 1,4-NQ or 1,4-DHN on enzyme activity indicates that the conversion of 4-OH-PL to the reactive inhibitor occurs within the active site of the enzyme and that the reactive species, possibly 1,4-NQ, does not dissociate from the enzyme.
